Back to Search Start Over

GABA B R-Induced EGFR Transactivation Promotes Migration of Human Prostate Cancer Cells.

Authors :
Xia S
He C
Zhu Y
Wang S
Li H
Zhang Z
Jiang X
Liu J
Source :
Molecular pharmacology [Mol Pharmacol] 2017 Sep; Vol. 92 (3), pp. 265-277. Date of Electronic Publication: 2017 Apr 19.
Publication Year :
2017

Abstract

G protein-coupled receptors (GPCRs) and receptor tyrosine kinases (RTKs) act in concert to regulate cell growth, proliferation, survival, and migration. Metabotropic GABA <subscript>B</subscript> receptor (GABA <subscript>B</subscript> R) is the GPCR for the main inhibitory neurotransmitter GABA in the central nervous system. Increased expression of GABA <subscript>B</subscript> R has been detected in human cancer tissues and cancer cell lines, but the role of GABA <subscript>B</subscript> R in these cells is controversial and the underlying mechanism remains poorly understood. Here, we investigated whether GABA <subscript>B</subscript> R hijacks RTK signaling to modulate the fates of human prostate cancer cells. RTK array analysis revealed that the GABA <subscript>B</subscript> R-specific agonist baclofen selectively induced the transactivation of EGFR in PC-3 cells. EGFR transactivation resulted in the activation of ERK1/2 by a mechanism that is dependent on G <subscript>i/o</subscript> protein and that requires matrix metalloproteinase-mediated proligand shedding. Positive allosteric modulators (PAMs) of GABA <subscript>B</subscript> R, such as CGP7930, rac-BHFF, and GS39783, can function as PAM agonists to induce EGFR transactivation and subsequent ERK1/2 activation. Moreover, both baclofen and CGP7930 promoted cell migration and invasion through EGFR signaling. In summary, our observations demonstrated that GABA <subscript>B</subscript> R transactivated EGFR in a ligand-dependent mechanism to promote prostate cancer cell migration and invasion, thus providing new insights into developing a novel strategy for prostate cancer treatment by targeting neurotransmitter signaling.<br /> (Copyright © 2017 by The American Society for Pharmacology and Experimental Therapeutics.)

Details

Language :
English
ISSN :
1521-0111
Volume :
92
Issue :
3
Database :
MEDLINE
Journal :
Molecular pharmacology
Publication Type :
Academic Journal
Accession number :
28424220
Full Text :
https://doi.org/10.1124/mol.116.107854